Aeglea Biotherapeutics Inc buy melinda
Start price
18.09.18
/
50%
?7.72
Target price
01.10.18
€9.83
Performance (%)
12.51%
End price
01.10.18
€8.68
Summary
This prediction ended on 01.10.18 with a price of €8.68. The prediction had a final performance of 12.51%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Aeglea Biotherapeutics Inc | - | - | - | - |
| iShares Core DAX® | -0.130% | 1.601% | 13.900% | 16.793% |
| iShares Nasdaq 100 | -5.156% | -2.343% | 30.120% | 47.391% |
| iShares Nikkei 225® | -3.402% | 2.990% | 12.946% | 9.565% |
| iShares S&P 500 | -1.733% | 0.290% | 28.669% | 44.958% |
Comments by melinda for this prediction
In the thread Aeglea Biotherapeutics Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 08/10 | 15:00 Assemblée générale
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer.
It develops pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer.
The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Nombre d'employés : 43 personnes.
Stopped prediction by melinda for Aeglea Biotherapeutics Inc
Aeglea Biotherapeutics Inc
Start price
Target price
Perf. (%)
?7.22
31.03.19
31.03.19
€8.12
31.07.19
31.07.19
12.25%
31.07.19
31.07.19
Aeglea Biotherapeutics Inc
Start price
Target price
Perf. (%)
?6.34
25.04.17
25.04.17
€6.77
07.06.17
07.06.17
-48.34%
07.06.17
07.06.17
Aeglea Biotherapeutics Inc
Start price
Target price
Perf. (%)
?3.86
08.02.17
08.02.17
€4.69
15.02.17
15.02.17
22.48%
15.02.17
15.02.17